Please login to the form below
Trevena
This page shows the latest Trevena news and features for those working in and with pharma, biotech and healthcare.
Trevena gets second go at FDA approval for pain drug
FDA sets review completion date of 7 August 2020. US biotech Trevena has resubmitted its lead drug oliceridine for moderate-to-severe pain in the US, 18 months after it was ... The new review – which the FDA considers a class two resubmission so will
Latest news
-
AcelRX’s potent opioid tablets set to win FDA backing for pain relief
BMIs. Meanwhile, Trevena’s intravenous opioid olicerdine for the management of moderate-to-severe acute pain in adult patients narrowly missed out on a recommendation from the committee, with eight members
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Heart failure therapy embarks on a new era
in the EU and US last year but still in development); Allergan/Trevena's AT1 receptor antagonist TRV207l and off-patent compound perhexiline, thought to improve the efficiency of heart muscle
-
Pharma deals during November 2013
Biotechs including Xencor, Trevena and Vital Therapies have also postponed their IPOs citing unfavourable market conditions.
-
Pharma deals during October 2013
75. Trevena. TRV027, GPCR biased ligand for acute heart failure (phase II).
-
Deal Watch table for May 2013
Rare disease medicines $76m sales. 693. Trevena/ Forest . Option to license equity.
-
Pharma deals during May 2013
The deals that fall into this category are: Forest's $460m option to license a phase II acute heart failure treatment from Trevena; Merck's $430m licence of diabetes type 2
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Former Pfizer R&D head LaMattina to advise Ziarco
Trevena Pharmaceuticals.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Amgen reports positive results for Otezla in psoriatic arthritis
- Supply chain challenges in 2023
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
